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Background: To determine prognostic factors and build a model to 
predict 1-year overall survival (OS) and 6-month progression-free 
survival (PFS) in advanced non–small-cell lung cancer (NSCLC) 
patients treated with first-line paclitaxel and carboplatin with or with-
out bevacizumab.
Materials and Methods: We analyzed 26 pretreatment clinical 
variables in 850 NSCLC patients treated in the randomized Eastern 
Cooperative Oncology Group 4599 study. Univariate and multi-
variate analyses were performed to identify prognostic factors. Cox 
regression with 50% randomly sampled data was used to build nomo-
grams with a prognostic score assigned to each factor. The model was 
validated with the remaining 50% of data.
Results: Eleven poor factors for OS (hazard ratio) were as fol-
lows: skin metastasis (4.49), body mass index less than 18.5 (2.09), 
increased serum lactate dehydrogenase (1.74), adrenal metastasis 
(1.52), performance status greater than 0 (1.45), low serum albumin 
(1.45), men (1.39), bone metastasis (1.39), large cell/not otherwise 
specified histology (1.29), mediastinal nodal metastasis (1.23), and 
treatment without bevacizumab (1.18). Seven poor factors for PFS 
were as follows: skin metastasis (3.13), treatment without bevaci-
zumab (1.52), bone metastasis (1.41), liver metastasis (1.40), low 
serum albumin (1.39), performance status greater than 0 (1.21), 
and mediastinal nodal metastasis (1.14). Based on these factors, 
we built and validated two nomograms predicting 1-year OS and 
6-month PFS.
Conclusion: Using our proposed models, the probability of survival 
with first-line paclitaxel and carboplatin with or without bevacizumab 
in nonsquamous NSCLC patients can be estimated. These prognostic 
models provide a tool for research design and clinical decision mak-
ing, such as patient stratification and therapy selection.
Key Words: Prognostic models, Nomograms, Non–small-cell lung 
cancer, Chemotherapy, Bevacizumab.
(J Thorac Oncol. 2012;7: 1361–1368)
In 2005, we reported a clinical model to predict survival in chemo-naïve patients with advanced non–small-cell lung 
cancer (NSCLC) treated with third-generation platinum-based 
chemotherapy doublets.1 Six clinical prognostic factors were 
determined and a nomogram was built based on the data from 
the two randomized phase III Eastern Cooperative Oncology 
Group (ECOG) studies, ECOG 5592 and ECOG 1594.2,3 Since 
then, ECOG investigators have published the pivotal random-
ized study ECOG 4599, which demonstrated the benefit of add-
ing the vascular endothelial growth factor (VEGF)–targeted 
monoclonal antibody bevacizumab to the standard regimen 
of paclitaxel and carboplatin (PC) in nonsquamous NSCLC.4 
Patients receiving the triplet regimen of PC and bevacizumab 
(PCB) lived significantly longer than those treated with PC 
alone with a hazard ratio (HR) of 0.79 (p = 0.003). Based on 
these results, bevacizumab was approved for use in combina-
tion with PC as first-line therapy for nonsquamous NSCLC.
In spite of proven survival benefits, bevacizumab is 
associated with certain specific, sometimes fatal, adverse 
events, including hemorrhages, organ perforation, hyperten-
sion, and proteinuria. In addition, significant neutropenia and 
thrombocytopenia are seen more often in those treated with 
the triplet PCB. Therefore, it is critical to identify patients who 
may benefit the most, and conversely those who may benefit 
the least, with bevacizumab. Unfortunately, despite extensive 
investigation on several potential biomarkers for antiangio-
genic therapy, to date no biomarkers for bevacizumab have 
been validated for clinical use. Instead, the decision to use 
bevacizumab in NSCLC is based on clinical features such as 
histology and history of hemoptysis.
Therefore, we retrospectively analyzed ECOG 4599 
data to identify clinical and laboratory characteristics that 
would predict survival of NSCLC patients receiving first-line 
treatment with PC with or without bevacizumab. We used 
this data to build a nomogram to estimate the probability of 
survival in this patient population.
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PATIENTS AND METHODS
Patients
We retrospectively analyzed data of 850 eligible patients 
with advanced NSCLC who were randomized to receive first-
line therapy of PCB or PC in the study ECOG 4599. The inclu-
sion/exclusion criteria and treatment regimens were previously 
described in the original report by Sandler et al.4 In short, 
patients were randomly assigned to receive paclitaxel 200 mg/
m2 and carboplatin at area under the curve of 6, with or with-
out bevacizumab 15 mg/kg every 3 weeks for up to six cycles. 
Patients with at least stable disease in the PCB arm continued 
bevacizumab until disease progression or unacceptable toxicity.
Statistical Analysis Methods
The primary objectives of this analysis are to deter-
mine prognostic factors to predict survival of NSCLC patients 
treated with first-line PC with or without bevacizumab, and 
to build nomograms to predict 1-year overall survival (1Y-
OS) and 6-month progression-free survival (6M-PFS). On 
the basis of our prior clinical model 1 and other analyses on 
prognosis in lung cancer,5–8 we selected 26 pretreatment clini-
cal and laboratory variables recorded in the database for this 
study(Table 1), including the following: treatment with or 
without bevacizumab, patient demographics, disease stage, 
performance status (PS), histology subtypes, metastatic sites/
organs, number of metastatic sites, prior radiation therapy, 
body mass index (BMI; underweight < 18.5, normal weight 
18.5–24.9, overweight 25–29.9, and obesity ≥ 30); body sur-
face area (< or ≥ 2 m2), and baseline laboratory tests including 
serum albumin level (< or ≥ lower limit of normal), serum 
lactate dehydrogenase (LDH; ≤ or > upper limit of normal), 
and proteinuria by urinary analysis (negative, trace or 1or > 1).
A univariable Cox regression analysis was used to 
assess the association between each variable and outcome. 
Multivariable stepwise Cox models were then fitted for final 
variable selection of prognostic factors. Using 50% randomly 
sampled data (test set), we built the two nomograms predict-
ing 1Y-OS and 6M-PFS. Prognostic scores (P/S) used in each 
nomogram are derived from the absolute values of the esti-
mated log HRs (from the multivariate Cox model built on the 
test set) multiplied by 100. The prediction models were then 
validated with the remaining 50% of data (validation set).
RESULTS
As reported in the original ECOG 4599 paper by 
Sandler et al., PCB significantly prolonged survival in com-
parison with chemotherapy alone, with median OS of 12.3 
months versus 10.3 months, 1Y-OS of 51% versus 44%, with 
a death HR of 0.79 (p = 0.003), and median PFS of 6.2 months 
versus 4.5 months, with a HR for disease progression of 0.66 
(p < 0.001).4 A summary of baseline clinical and laboratory 
variables of 850 patients included in this analysis is presented 
in Table 1. Patients were randomized equally to PC and PCB 
arms. One of four patients were 70 years or older. More than 
two thirds had adenocarcinoma (AC) and almost half were 
women. A small number of patients had AC with lepidic pat-
tern (formerly bronchioalveolar carcinoma) (3%) or large-cell 
TABLE 1.  Patient Characteristics
Patient Characteristics
Patients (Total N = 850)
n (%)
Bevacizumab treatment
 Yes 417 (49)
 No 433 (51)
Age
 <70 648 (76)
 ≥70 202 (24)
Sex
 Female 387 (46)
 Male 463 (54)
Race
 White 730 (86)
 Other 120 (14)
Stage
 IIIB 105 (12)
 IV/Recurrent 745 (88)
Performance status
 0 343 (40)
 1 507 (60)
Histology
 AC 586 (69)
 ACLP 23 (3)
 LCC 46 (5)
 NOS 160 (19)
 Other 32 (4)
Hilar nodes
 Present 335 (39)
Mediastinal nodes
 Present 439 (52)
Supraclavicular/scalene nodes
 Present 72 (8)
Pleural effusion
 Present 322 (38)
Malignant effusion
 Present 169 (20)
Pleural metastasis
 Present 223 (26)
Ipsilateral lung metastasis
 Present 381 (45)
Contralateral lung metastasis
 Present 280 (33)
Liver metastasis
 Present 163 (19)
Bone/BM metastasis
 Present 267 (31)
Adrenal metastasis
 Present 125 (15)
Skin metastasis
 Present 12 (1.4)
Distant metastasis > 3 sitesa
 Present 165 (19)
(Continued)
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carcinoma (5%), whereas 19% had not otherwise specified 
(NOS) NSCLC. Of all metastatic organs, the most common 
site was mediastinal nodes (52%). Other common metastatic 
sites included ipsilateral (45%) or contralateral (33%) lung, 
pleura (20% reported as malignant effusion and 26% pleu-
ral metastasis), and bone (31%). The least reported metastatic 
organ was skin (1.4%). More than half of the patients were 
overweight (36%) or obese (20%), whereas only 4% were 
considered underweight with BMI less than 18.5. Serum albu-
min was low in 28% of the patients, serum LDH was high in 
32%, and proteinuria (trace or higher) was seen in 20%.
Prognostic Factors and Nomogram 
Predicting 1Y-OS
To determine independent prognostic factors predict-
ing OS, univariate and multivariate Cox models were fitted. 
Out of the 26 variables analyzed in univariate analysis, 15 are 
associated with poor survival. The Cox multivariate regres-
sion model further identified 11 independent poor prognostic 
factors (Table 2).
Based on those 11 independent prognostic markers, 
we built a nomogram to predict 1Y-OS using 50% randomly 
sampled data (Figure 1A). In this model, each poor prognostic 
factor is assigned a P/S correlating with 1Y-OS prognosis. A 
TABLE 1.  (Continued)
Patient Characteristics
Patients (Total N = 850)
n (%)
Prior radiation therapy
 Yes 70 (8)
 No 780 (92)
Body mass index
 <18.5 30 (4)
 18.5–24.9 349 (41)
 25–29.9 304 (36)
 ≥30 167 (20)
Body surface area
 ≥2 269 (32)
 <2 581 (68)
Low serum albumin (<LLN)
 Present 240 (28)
High serum LDH (>ULN)
 Present 273 (32)
Proteinuria
 Negative 673 (80)
 Trace 136 (16)
 1+ or higher 34 (4)
aIpsilateral or contralateral lung, pleura, liver, adrenal, brain, bone, BM, skin.
AC, adenocarcinoma; ACLP, adenocarcinoma with lepidic pattern (bronchio-alveolar 
carcinoma); LCC, large-cell carcinoma; NOS, not otherwise specified; BM, bone marrow; 
LLN, lower limit of normal; LDH, lactate dehydrogenase; ULN, upper limit of normal.
TABLE 2.  Independent Poor Prognostic Factors of Overall 
Survival
Patient Characteristics HR p Value
Prognostic 
Score
Skin metastasis 4.49 <0.0001 130
Low BMI < 18.5 2.09 0.0003 81
High serum LDH (>ULN) 1.74 <0.0001 48
Adrenal metastasis 1.52 0.0002 52
PS 1 (vs. PS 0) 1.45 <0.0001 35
Low serum albumin (<LLN) 1.45 <0.0001 32
Sex: male 1.39 0.0002 37
Bone metastasis 1.39 0.0002 29
Histology: LCC/NOS (vs. AC/ACLP) 1.29 0.006 30
Mediastinal nodes 1.23 0.02 42
No bevacizumab (PC alone) 1.18 0.05 25
HR, hazard ratio; BMI, body mass index; LDH, lactate dehydrogenase; ULN, upper 
limit of normal; PS, performance status; LLN, lower limit of normal; LCC, large-cell 
carcinoma; NOS, not otherwise specified; AC, adenocarcinoma; ACLP, adenocarcinoma 
with lepidic pattern (bronchio-alveolar carcinoma); PC, paclitaxel and carboplatin.
FIGURE 1. Prognostic nomograms predicting: (A) 1-year overall survival (OS); (B) 6-month progression-free survival (PFS). BM, 
bone marrow; BAC, bronchoalveolar carcinoma; LLN, lower limit of normal; PS, performance status; LDH, lactate dehydroge-
nase; ULN, upper limit of normal; BMI, body mass index.
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higher score implies a poorer survival outcome. The factor 
with the poorest prognosis is skin metastasis (HR = 4.49; P/S = 
130), followed by a low BMI less than 18.5 (HR = 2.09, P/S = 
81). The remaining nine poor independent prognostic factors 
are as follows: increased serum LDH (HR = 1.74, P/S = 48), 
adrenal metastasis (HR = 1.52, P/S = 52), PS ECOG 1 (HR 
1.45, P/S = 35), low serum albumin (HR = 1.45, P/S = 32), 
male sex (HR = 1.39, P/S = 37), bone metastasis (HR 1.39, 
P/S = 29), large cell or NOS histology (HR = 1.29, P/S = 30), 
mediastinal nodal involvement (HR = 1.23, P/S = 42), and 
treatment without bevacizumab (HR = 1.18, P/S = 25).
Prognostic Factors and Nomogram 
Predicting 6M-PFS
Using a similar method, we fit clinical data of ECOG 
4599 into Cox models to identify independent poor prognostic 
factors (Table 3) and build a nomogram (Fig. 1B) to predict 
6M-PFS. From the 26 clinical variables, we identified 15 
poor factors in univariate analysis. In multivariate analysis, 
only seven stood out as independent poor factors for 6M-PFS, 
including the following: skin metastasis (HR = 3.13, P/S = 
103), treatment without bevacizumab (HR = 1.52, P/S = 37), 
bone metastasis (HR = 1.41, P/S = 27), liver metastasis (HR = 
1.40, P/S = 33), low serum albumin (HR = 1.39, P/S = 29), 
PS ECOG 1 (HR = 1.21, P/S = 19), and mediastinal nodal 
involvement (HR = 1.14, P/S = 21).
Validation of the Nomograms
The 1Y-OS and 6-M PFS nomograms were constructed 
from the test set of 50% randomly sampled data and validated 
by the validation set of the remaining 50% data. To validate 
the models, patients in the validation set were divided into 
quartile groups based on their P/S: low risk, low-intermediate 
risk, high-intermediate risk, and high risk. As shown in Figure 
2, the predicted survival (x axis) for each quartile group was 
compared with the observed/actual survival (y axis). The dot-
ted line in the figure illustrates the ideal scenario in which the 
predicted survival perfectly matches the observed survival. 
We found that the predicted survival was within the 95% 
confidence intervals of the observed survival (arrows), and 
both 1Y-OS and 6M-PFS lines follow the ideal line. The find-
ing demonstrates a good agreement between predicted and 
observed survivals.
Case Examples on How to Use 
the Prognostic Nomograms
Using our nomograms, one could predict the probability 
of an NSCLC patient surviving 1 year or longer and achiev-
ing a 6-month or longer disease-free progression interval 
TABLE 3.  Independent Poor Prognostic Factors of 
Progression-Free Survival
Patient Characteristics HR p Value
Prognostic 
Score
Skin metastasis 3.13 0.0001 103
No bevacizumab (PC alone) 1.52 <0.0001 37
Bone metastasis 1.41 <0.0001 27
Liver metastasis 1.40 0.0002 33
Low serum albumin (<LLN) 1.39 <0.0001 29
PS 1 (vs. PS 0) 1.21 0.01 19
Mediastinal nodes 1.14 0.07 21
HR, hazard ratio; PC, paclitaxel and carboplatin; LLN, lower limit of normal; PS, 
performance status.
FIGURE 2.  Comparison of predicted survival with observed survival of quartile groups of patients in the validation set:  
(A) 1-year overall survival; (B) 6-month progression-free survival (PFS). The dotted line is the “ideal” line if there is a perfect 
match between predicted and observed survival. The vertical arrows represent 95% confidence intervals of observed survival.
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with first-line PC with or without bevacizumab. For example, 
patient 1, a woman with large-cell lung cancer, ECOG PS of 
1, BMI less than 18.5, bone metastasis, serum albumin below 
the lower limit of normal, and receiving PC as first-line treat-
ment, has a total P/S of 232 for OS and 112 for PFS (Figure 
3A, B). On the nomograms, those scores correspond to an 
estimate 1Y-OS chance of 13% and 6M-PFS chance of 26%. 
However, if this patient was treated with the triplet therapy of 
PCB, her total P/S would be 207 for OS and 75 for PFS. Thus, 
her predicted 1Y-OS and 6M-PFS would be 20% and 40%, 
respectively.
In another example, patient 2 is a woman with a lung 
AC with a malignant effusion who has none of the poor base-
line factors (Figure 3C, D). Should she be treated with PCB, 
her total P/S would be 0 for both OS and PFS, and as such, 
her estimated 1Y-OS and 6M-PFS chance would be 81% and 
65%. However, if she were treated with PC alone, her P/S 
would be 25 for OS and 37 for PFS, corresponding to a 1Y-OS 
and 6M-PFS chance of 76% and 53%, respectively.
In both patients in the above examples, adding bevaci-
zumab to PC prolongs both 1Y-OS and 6M-PFS. However, 
the relative gain with bevacizumab seems more profound in 
the first patient who has a much worse prognosis than the sec-
ond patient who has none of baseline poor prognostic factors. 
Indeed, the addition of bevacizumab in patient 1 results in a 
50% improvement in 1Y-OS (from 13% to 20%) whereas in 
patient 2, bevacizumab only leads to a 7% improvement in 
survival (from 76% to 81%).
FIGURE 3. Examples of the nomograms: (A) predicted 1-year overall survival (OS) of patient 1 who is a woman with large-cell 
lung cancer (P/S 30), ECOG PS 1 (P/S 35), BMI less than 18.5 (P/S 81), bone metastasis (P/S 29), and low serum albumin (P/S 
32). Treated with PC alone (P/S 25), her total prognostic score is 232 points (30 + 35 +81 + 29 + 32 + 25). If bevacizumab is 
added to the doublet, her total prognostic score is 207 points (30 + 35 + 81 + 29 + 32); (B) predicted 6-month PFS of patient 
1. Treated with PC alone, her prognostic score is 112 points (19 + 27 + 29 + 37). If bevacizumab is added to the doublet, her 
prognostic score is 75 points (19 + 27 + 29); (C) predicted 1-year OS of patient 2 who is a woman with an adenocarcinoma of 
the lung with malignant effusion, otherwise having none of poor baseline factors. Treated with PC alone, her total prognostic 
score is 25 points. If bevacizumab is added to the doublet, her total prognostic score is 0; (D) predicted 6-month PFS of patient 
2. Treated with PC alone, her prognostic score is 37 points. If bevacizumab is added to the doublet, her prognostic score is 0. 
BM, bone marrow; BAC, bronchoalveolar carcinoma; LLN, lower limit of normal; LDH, lactate dehydrogenase; ULN, upper limit 
of normal; PCB, PC and bevacizumab; PC, paclitaxel and carboplatin; BMI, body mass index; PFS, progression-free survival; 
ECOG, Eastern Cooperative Oncology Group.
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DISCUSSION
During the last few decades, progresses in biology, 
diagnostics, and therapy have resulted in a slow but steady 
improvement in the treatment of advanced NSCLC. Overall 
median survival of patients with metastatic disease improved 
from 5 to 6 months in the 1980s to 12 months at present with 
the incorporation of targeted drugs such as bevacizumab into 
conventional chemotherapy. However, survival among patients 
varies significantly, based on tumor biology and clinical fac-
tors, such as poor PS and significant weight loss. Other factors, 
including sex, metastasis, or laboratory abnormalities such as 
leukocytosis and increased LDH, were suggested in some but 
not all studies. Table 4 shows the findings of five large retro-
spective analyses based on selected randomized studies from 
cooperative groups conducted within the last three decades.1,5–7
In our previous analysis, which was based on ECOG 
5592 and ECOG 1594, we found six poor prognostic fac-
tors predicting survival of NSCLC patients treated with 
platinum-based doublets involving paclitaxel, docetaxel, or 
gemcitabine, including the following: skin metastasis, lower 
PS of 1 or 2, loss of appetite, liver metastasis, more than or 
equal to four metastatic sites, and no prior surgery.1 There are 
several differences between our previous and current analysis. 
This analysis is based on the ECOG 4599 trial, which accrued 
TABLE 4.  Survival Prognostic Factors and Prediction Models for Non–Small-Cell Lung Cancer from Five Retrospective Analyses
ECOG SWOG ELCWP ECOG ECOG
Finkelstein, 19865 Albain, 19916 Paesmans, 19957 Hoang, 20051 Hoang, 2011
Database 2 Phase III 5 Phase III 3 Phase III 2 Phase III 1 Phase III
(EST 2575 and 1581) 9 Phase II 4 Phase II (ECOG 5592 and 1594) (ECOG 4599)
Patient no. 893 2531 1052 1436 850
Disease stage Metastatic Locally advanced or 
metastatic
Unresectable I–IV Wet IIIB, IV, or recurrent Wet IIIB, IV, or 
recurrent
Histology Any NSCLC histology Any NSCLC histology Any NSCLC histology Any NSCLC histology Nonsquamous NSCLC
Line of treatment First-line First-line or previously 
treated
First-line or previously 
treated
First-line First-line
Chemotherapy 
regimens
Various older platin 
and nonplatin-based 
regimens
Various older platin 
and nonplatin-based 
regimens; mono vs. 
combined
Various platin-based, 
second-generation 
regimens; mono vs. 
combined
Platin-based, third-
generation doublets
Paclitaxel, carboplatin 
with or without 
bevacizumab
Survival
 Median (mos) <6 5.1 7 8.2 10.3/12.3a
 1 yr (%) 19 16 — 33 44/51a
 2 yrs (%) 4 — 7.4 11 15/23a
No. of factors  
analyzed
36 15 (not all patients) 23 27 26
Independent negative 
survival prognostic 
factors identified 
from multivariate 
analyses
1. Lower PS (1–2)
2. Bone metastasis
3. Sex: male
4. Weight loss
5. Subcutaneous 
metastasis
6. LCC
7. Shoulder/arm pain
8. Liver metastasis
All patients:
1. Lower PS (≥2)
2. Nonplatin drugs
3. Sex: male
4. Age < 70
PS 0–1 patients:
1. Hb < 11
2. Abnormal LDH
3. Abnormal calcium
4. ≥2 metastatic lesions
5. Nonplatin drugs
1. Stage IV (vs. earlier 
stages)
2. Lower PS (≤70)
3. Increased WBC
4. Skin metastasis
5. Increased calcium
6. Abnormal ANC
7. Age > 60
8. Sex: male
1. Skin metastasis
2. Lower PS (1–2)
3. Loss of appetite
4. Liver metastasis
5. ≥ 4 metastatic sites
6. No prior lung surgery
1. Skin metastasis
2. Low BMI <18.5
3. Increased LDH
4. Adrenal metastasis
5. Lower PS (1)
6. Low serum albumin
7. Sex: male
8. Bone metastasis
9. LCC/NOS histology
10. Mediastinal nodal 
metastasis
11. No bevacizumab 
(PC alone)
Survival prediction 
model or  
prognostic 
subgroups
Discriminant function 
requiring calculation 
to predict if an indi-
vidual will survive 
> 1 yr or not
Three prognostic 
subgroups based on 
recursive partitioning 
and amalgamation
Four prognostic  
subgroups with 
different 1- and 2-yr 
survival, based on 
recursive partitioning 
and amalgamation
Nomogram with a 
scoring system to 
predict 1- and 2-yr 
survival probability of 
individual patients
Nomogram with a  
scoring system to 
predict probability  
of 1-yr survival  
and 6-mo PFS of 
individual patients
aWithout bevacizumab/with bevacizumab.
ECOG, Eastern Cooperative Oncology Group; SWOG, Southwest Oncology Group; ELCWP, European Lung Cancer Working Party; NSCLC, non–small-cell lung cancer; 
PS,  performance status; BMI, body mass index; LDH, lactate dehydrogenase; WBC, white blood count; Hb, hemoglobin; ANC, absolute neutrophil count; LCC, large-cell carcinoma; 
NOS, not otherwise specified; PC, paclitaxel and carboplatin; PFS, progression-free survival.
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bevacizumab-eligible population only (nonsquamous histol-
ogy, no significant hemoptysis). Furthermore, we included 
both clinical and laboratory variables. More importantly, the 
treatment regimen involved PC with or without bevacizumab.
In this analysis, 11 poor survival factors were identi-
fied. Similar to our previous report, we found that skin metas-
tasis carries the worst survival prognosis with a higher HR 
(4.49) and P/S (130) in the 1Y-OS model. Skin metastasis also 
predicted the worst 6M-PFS. Although skin metastasis from 
primary lung cancer is an uncommon event, reported in only 
4% to 12% of patients in prior ECOG studies involving all 
NSCLC histology subtypes, and in 1.4% in ECOG 4599, its 
presence likely suggests an aggressive biological behavior of 
the disease causing widespread metastasis. Other investiga-
tors also found the negative impact of skin or subcutaneous 
spread on survival in NSCLC.5,7
Significant weight loss of more than 5% to 10% total 
body weight within a 6-month period and loss of appetite have 
been considered among the most important negative prognos-
tic factors in NSCLC. However, not all patients are able to 
quantify their weight loss. Therefore, in this study, we decided 
to evaluate BMI at baseline, prior to the start of chemotherapy, 
which can be calculated easily based on patient’s weight and 
height, as a potential prognostic factor. The results demon-
strated that underweight patients with BMI less than 18.5 had 
a poorer survival compared with those with normal or over-
weight patients (BMI ≥ 18.5), corresponding to the second 
highest HR (2.09). Interestingly, the relation between excess 
body weight and cancer mortality has been documented in 
many cancer types, although the underlying mechanism is not 
clear yet. In a report involving more than 900,000 American 
adults accrued in the prospective Cancer Prevention Study 
II, high BMI was generally associated with increased cancer 
related death rates in cohorts of both obese men and women 
with BMI greater than or equal to 35.0.8 That observation was 
seen across several solid and hematologic cancers, with the 
only exception being lung cancer. Indeed, contrary to other 
cancers, BMI was inversely correlated to lung cancer mortal-
ity. The relative risk of lung death in cohorts with BMI greater 
than or equal to 35.0 in that study was approximately 0.67. 
Low serum albumin level is also a poor prognostic OS in our 
model, with an HR of 1.45. It is possible that low BMI, low 
serum albumin, and weight loss/loss of appetite all are bio-
logical indicators of an aggressive cancer leading to a quick 
decline in nutritional and overall general health status.
Accumulating data have suggested that there is a sex 
difference between women and men with lung cancer.9 Some 
studies have suggested that women are more susceptible to 
carcinogenic effects of cigarette smoking.10,11 However, female 
patients with NSCLC are more likely to be never-smokers,12 
have AC,9 harbor mutations in the EGF receptor,13 and live 
longer than their male counterparts with chemotherapy.9 In 
this analysis, although there was no difference in PFS, men 
had a lower chance of surviving at 1 year, with an HR of 1.39. 
The difference in outcome suggests sex is an important factor 
in designing clinical trials, and that sex should be a stratifica-
tion factor in randomized trials.
In our analysis, patients with large-cell carcinoma or 
NOS histology had a poorer survival compared with those 
with AC or AC with lepidic pattern suptype, with an HR of 
1.29. It was unclear whether the histology of NOS cases was 
undefined because of poor histological differentiation or lack 
of tissue samples from fine needle aspiration. Patients with 
poorly differentiated, high-grade cancer may have more 
aggressive course and poorer prognosis.
Our study demonstrated that increase in LDH was sig-
nificantly associated with shorter 1Y-OS with an HR of 1.74. 
LDH is an enzyme, which catalyzes the forward and backward 
conversion of pyruvate to lactate, an important step in the pro-
cess of cellular glycolysis and energy production. Cancer cells 
primarily metabolize glucose into lactate through the anerobic 
glycolysis (Warburg effect), whereas most normal cells rely 
on the more efficient oxidative phosphorylation in mitochon-
dria to produce adenosine triphosphate. The isozyme M-LDH 
(LDH-5) is increased in several human tumors compared with 
normal tissues,14 and elevated serum LDH is associated with 
chemotherapy and radiation resistance15 and poor prognosis in 
a variety of cancers including NSCLC.6,15,16 The overexpres-
sion of LDH-5 in NSCLC tumor samples was linked to the 
expression of several angiogenic markers (VEGF, basic fibro-
blast growth factor [bFGF], and bFGF receptor), the hypoxia-
inducible factor 1α, and survival in patients with resected 
disease.15,17 Findings from our study and those of others sug-
gest that serum LDH and albumin are two simple blood tests, 
which can be used to evaluate prognosis in NSCLC patients. 
However, it should be noted that LDH is not specific, as it can 
also be elevated in patients with underlying medical diseases 
such as cardiac, lung, and liver disorders. Prospective studies 
are needed to validate the prognostic value of tumor LDH-5 
expression for clinical use.
Finally, the addition of bevacizumab to chemotherapy is 
a positive prognostic factor for improved PFS and 1Y-OS rate. 
In regard to PFS, bevacizumab is the second most important 
factor, second only to skin metastasis. Compared with trip-
let therapy PCB, treatment with PC alone correlated with an 
HR of 1.52 for PFS. However, the benefit of bevacizumab on 
1Y-OS appeared relatively modest in comparison with other 
factors. Indeed, among the 11 poor factors predicting 1Y-OS, 
bevacizumab impacts the least with an HR of 1.18 in patients 
receiving chemotherapy alone. Although survival advantages 
of bevacizumab in NSCLC have been proven, the drug is 
associated with certain morbid and fatal adverse effects such 
as bleeding, gastrointestinal perforation, or fistula. Because 
of the modest gain by adding bevacizumab to chemotherapy 
in patients without poor prognostic factors (such as patient 
2 in the above example), patients with good factors and bor-
derline risks to bevacizumab (for example, hemoptysis < 1/2 
teaspoon, labile hypertension) may elect a nonbevacizumab 
containing regimen, either with standard chemotherapy or 
enrolling into clinical trials.
Multiple potential biomarkers for bevacizumab and 
other antiangiogenic agents such as VEGF, bFGF, intercel-
lular adhesion molecule, E-selectin, thrombospondin-2, and 
microvessel density have been investigated in clinical trials in 
lung cancer and other cancers.18–21 However, to date, no bio-
markers for antiangiogenic therapy have been validated yet for 
clinical use. Thus, these nomograms may be helpful in identi-
fying NSCLC patients most likely to benefit from the addition 
1368 Copyright © 2012 by the International Association for the Study of Lung Cancer
Hoang et al. Journal of Thoracic Oncology  •  Volume 7, Number 9, September 2012
of bevacizumab to chemotherapy. By doing so, one may maxi-
mize the therapeutic gain, while minimizing potential morbid-
ity and mortality and reduce the cost to the health care system.
In conclusion, our analysis identified several clinical 
factors predicting survival in nonsquamous NSCLC patients 
treated with first-line PC with or without bevacizumab. Our 
nomograms offer a tool to estimate the possibility of survival. 
Those prognostic factors and models may help investigators 
in designing clinical trials and assist clinicians in selecting the 
most appropriate therapy for their patients.
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